Loading clinical trials...
Loading clinical trials...
International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From Iniparib Following Completion of a Phase 1, 2 or 3 Parental Study
Conditions
Interventions
Iniparib (SAR240550/BSI-201)
Carboplatin
+5 more
Locations
32
United States
Investigational Site Number 840013
Birmingham, Alabama, United States
Investigational Site Number 840033
Santa Maria, California, United States
Investigational Site Number 840046
Vallejo, California, United States
Investigational Site Number 840008
Denver, Colorado, United States
Investigational Site Number 840027
Jacksonville, Florida, United States
Investigational Site Number 840063
Augusta, Georgia, United States
Start Date
May 1, 2012
Primary Completion Date
September 1, 2016
Completion Date
September 1, 2016
Last Updated
September 19, 2017
NCT06898450
NCT06658951
NCT05719558
NCT05101070
NCT06716138
NCT06307795
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions